Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + normal saline is a combination therapy being investigated by Sohag University for the management of advanced hip damage in patients with axial spondyloarthritis. This intervention combines hip denervation, achieved through the injection of lidocaine (a local anesthetic), with intra-articular hydration using normal saline. Lidocaine functions by blocking voltage-gated sodium channels, thereby inhibiting the conduction of pain signals from the affected joint. Normal saline is injected into the hip joint to provide mechanical hydration, which may improve joint mobility and reduce friction. This combination is specifically targeted at patients with high BASRI scores (3 and 4) to alleviate pain and improve functional outcomes. The therapy is administered via perineural injection for denervation and intra-articular injection for hydration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + normal saline.